Contrasting Sangamo Therapeutics (NASDAQ:SGMO) and Agios Pharmaceuticals (NASDAQ:AGIO)

Sangamo Therapeutics (NASDAQ:SGMO – Get Free Report) and Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, profitability, risk and earnings.

Profitability

This table compares Sangamo Therapeutics and Agios Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sangamo Therapeutics -310.81% -2,662.06% -132.12%
Agios Pharmaceuticals -264.76% -34.63% -32.04%

Valuation and Earnings

This table compares Sangamo Therapeutics and Agios Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sangamo Therapeutics $39.55 million 0.78 -$122.93 million ($0.38) -0.19
Agios Pharmaceuticals $54.03 million 30.55 -$412.78 million ($6.32) -4.37

Sangamo Therapeutics has higher earnings, but lower revenue than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

56.9% of Sangamo Therapeutics shares are held by institutional investors. 4.1% of Sangamo Therapeutics shares are held by insiders. Comparatively, 5.4% of Agios Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations for Sangamo Therapeutics and Agios Pharmaceuticals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sangamo Therapeutics 2 0 1 0 1.67
Agios Pharmaceuticals 1 3 5 1 2.60

Sangamo Therapeutics presently has a consensus price target of $10.00, indicating a potential upside of 13,413.51%. Agios Pharmaceuticals has a consensus price target of $41.62, indicating a potential upside of 50.82%. Given Sangamo Therapeutics’ higher possible upside, equities research analysts clearly believe Sangamo Therapeutics is more favorable than Agios Pharmaceuticals.

Volatility and Risk

Sangamo Therapeutics has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500. Comparatively, Agios Pharmaceuticals has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500.

Summary

Agios Pharmaceuticals beats Sangamo Therapeutics on 9 of the 15 factors compared between the two stocks.

About Sangamo Therapeutics

(Get Free Report)

Sangamo Therapeutics is a biotechnology company developing genomic medicines for serious diseases. Its research focuses on modifying or regulating genes and using engineered cells to produce potential treatments. The company’s technology platform includes zinc finger proteins, including zinc finger nucleases (ZFNs), which are designed to target specific genetic sequences. Sangamo applies its technologies across gene therapy, cell therapy and gene regulation programs, with research spanning areas such as rare diseases and neurological disorders.

About Agios Pharmaceuticals

(Get Free Report)

Agios Pharmaceuticals is a biopharmaceutical company focused on developing medicines for rare genetic diseases, particularly blood disorders. Based in Cambridge, Massachusetts, the company applies research into cellular metabolism to identify potential treatments. Its marketed medicine, PYRUKYND (mitapivat), is approved in the United States to treat adults with pyruvate kinase deficiency, a rare inherited disorder that can cause anemia. Agios also develops therapies for other rare diseases, including additional blood disorders.

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.